Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q3 FY16 Earnings Presentation
18 slides from Dr. Lal Pathlabs's earnings presentation, Feb 12, 2016
Slide 1: Dr. Lal PathLabs Limited Q3 & 9M FY16 Results Presentation
Dr. Lal PathLabs Limited Q3 & 9M FY16 Results Presentation February 12, 2016
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q3 & 9M Financial Performance 4 Financial Trends 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Key Financial Highlights 9 Corporate Overview 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ stat
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 172 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,554 Patient Service diagnostic services Centers (PSCs) and 7,059 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralized IT panels
Slide 4: Key Highlights
Key Highlights Steady growth continues –outlook remains positive and promising Operational scale up of business in line with plan Strengthened position in core markets and expanding in new markets During 9M FY16 LPL reported: Total Revenue growth of 22% to Rs. 5,936 mn from Rs. 4,878 mn
Slide 5: Notes to Accounts
Notes to Accounts Prior to listing the Company’s equity shares, the accounting of options granted/shares issued against exercise of options under ESOP Plan 2010 was carried out on cash settled basis as per provisions of said plan. Accordingly, liability created of Rs. 166.3 mn as on September 30,
Slide 6: Q3 & 9M Financial Performance
Q3 & 9M Financial Performance Particulars (Rs. mn) Q3 FY16 Q3 FY15 Growth % 9M FY16 9M FY15 Growth % Total Revenues 1,885.7 1,558.3 21.0% 5,936.1 4,877.5 21.7% Total Expenditure 1,185.1 1,175.5 0.8% 4,380.2 3,755.8 16.6% EBITDA 700.6 382.8 83.0% 1,555.9 1,121.7 38.7% EBITDA (without ESOP reversal) 4
Slide 7: Financial Trends: Total Revenues
Financial Trends All figures in Rs mn Total Revenues Total Revenues 1886 1558 5936 4878 Q3FY15 Q3FY16 9MFY15 9MFY16 Revenue gains of 21% YoY in Q3 FY16 followed a combination of enhancement in volumes and steady realizations Traditionally Q3 is a slightly moderated quarter for patient inflows
Slide 8: Financial Trends: EBITDA
Financial Trends All figures in Rs mn EBITDA (Without ESOP Reversal) 427 1521 405 1359 Q3FY15 Q3FY16 9MFY15 9MFY16 Continued momentum in EBITDA (Without ESOP Reversal) with 12% YoY improvement in 9M FY16; 5.3% YoY gains in Q3 FY16 EBITDA Margins (Without ESOP Reversal) stood at 25.6% for 9M FY16
Slide 9: Financial Trends: PBT
Financial Trends All figures in Rs mn PBT (Without ESOP Reversal) 396 1445 364 1244 Q3FY15 Q3FY16 9MFY15 9MFY16 PBT (Without ESOP Reversal) growth during Q3 FY16 and 9M FY16 stood at 8.8% and 16.1% respectively Without the prior period charge of Rs. 16 mn in Q3 FY16 on account of new Bonus Act p
Slide 10: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 172 1,554 7,059 164 1,340 5,667 146 1,064 4,225 824 1,475 131 1,271 2,879 1,009 776 48 55 69 79 FY13 FY14 FY15 H1 FY16 FY13 FY14 FY15 H1 FY16 FY13 FY14 FY15 H1 FY16 No. of patients (mn) Franchised Owned No. of samples (mn) 21.
Slide 11: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “I am delighted to be sharing the first financial and operating performance of the Company as a listed entity and I extend a warm welcome to our public shareholders. I am proud to shar
Slide 12: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services . Initiatives to improve brand c
Slide 13: Key Financial Highlights
Key Financial Highlights Cash and cash equivalents as on December 31, 2015 of Rs. 2,579 mn Debt free Company with zero debt at net level Asset light balance sheet with fixed asset investments focused on specific goals and ability to generate attractive medium-to-long term returns Adequately
Slide 14: Corporate Overview
Corporate Overview • LPL Strategy for future growth • Experienced Management team 14
Slide 15: LPL Strategy for future growth
LPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 15
Slide 16: LPL Strategy for future growth
LPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Life
Slide 17: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Manoj Garg Shankha Banerjee Chief Financial Officer Chief Human Resources Officer COO – Strategic
Slide 18: Contact us
Contact us About Dr Lal PathLabs Limited (LPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and